Targeted Agent News Today

This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.

Heather Moore, CPP, PharmD, highlights key contributions from pharmacists in breast cancer treatment and identifies current unmet needs in the treatment landscape.

email article After close to a decade at the helm, Richard Schilsky, MD, has retired from his role as chief medical officer of the American Society of Clinical Oncology (ASCO). His legacy as the organizations first CMO will be what he calls the "ASCO research enterprise" -- launching ASCOs first-ever clinical trial, increasing its ability to conduct observational studies, and tapping into the 40,000-person membership for original survey-based research. "It was clear that while ASCO was ...